Century Therapeutics, Inc. (IPSC) Misses Q4 EPS by 168c

Century Therapeutics, Inc. (NASDAQ: IPSC) reported Q4 EPS of ($2.27), $1.68 worse than the analyst estimate of ($0.59). Revenue for the quarter came in at $5.2 million versus the consensus estimate of $2.27 million.

For earnings history and earnings-related data on Century Therapeutics, Inc. (IPSC) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance